The gatekeeper of reproductive hormones
A 10-residue peptide that activates KISS1R to trigger GnRH and reproductive hormone release.
Educational content. This page describes Kisspeptin-10 for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
A single IV bolus of kisspeptin-10 triggers sustained GnRH release (~17 minutes) and resets the endogenous GnRH pulse generator, delaying the next pulse by one full interpulse interval.[9]
Restored LH pulsatility and raised testosterone from 8.5 to 11.4 nmol/L in hypotestosteronemic men with type 2 diabetes, demonstrating that kisspeptin can bypass the metabolic suppression of the reproductive axis.[8]
Kisspeptin-10 (KP-10) is the shortest biologically active fragment of the kisspeptin family, a group of peptides encoded by the KISS1 gene on chromosome 1q32. The KISS1 gene was originally identified in 1996 as a metastasis suppressor in melanoma cells at Pennsylvania State University (the name derives from KI for Hershey, Pennsylvania, plus SS for suppressor sequence). Its role as the master regulator of reproductive hormone release was discovered in 2003 when loss-of-function mutations in its receptor (KISS1R, previously called GPR54) were found to cause hypogonadotropic hypogonadism.
Kisspeptin-10 has the amino acid sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2. All kisspeptin variants (KP-54, KP-14, KP-13, and KP-10) share this C-terminal decapeptide motif ending in an Arg-Phe-amide sequence, and all have equivalent binding affinity for KISS1R. The C-terminal amidation is absolutely critical for biological activity. KP-10 has a very short half-life of approximately 4 minutes, compared to about 28 minutes for the longer KP-54 variant.
Kisspeptin-10 binds KISS1R (a Gq/G11-coupled receptor) on GnRH neurons in the hypothalamus. Approximately 90% of GnRH neurons express this receptor. Activation triggers phospholipase C, which hydrolyzes PIP2 into IP3 (releasing intracellular calcium) and DAG (activating protein kinase C). Two simultaneous ion channel effects depolarize the neuron: activation of TRPC cation channels producing inward currents and closure of inward rectifier potassium channels removing repolarizing currents.
The resulting depolarization (~22.6 mV with an EC50 of ~2.8 nM) drives GnRH neurons to fire and release GnRH into the hypophysial portal vasculature, which reaches the anterior pituitary to stimulate LH and FSH release from gonadotropes. These gonadotropins then drive gonadal sex steroid production and gametogenesis.
In the arcuate nucleus, kisspeptin neurons co-express neurokinin B (NKB) and dynorphin, forming the KNDy neuron network that functions as the GnRH pulse generator. NKB initiates synchronized firing, kisspeptin delivers the signal to GnRH neurons, and dynorphin terminates the burst to create the interpulse interval. A separate kisspeptin population in the AVPV/preoptic area mediates estrogen positive feedback and drives the preovulatory LH surge in females.
The gatekeeper of reproductive hormones
Kisspeptin-10 activates KISS1R on GnRH neurons via Gq/G11 signaling, triggering phospholipase C activation, TRPC channel opening, and potassium channel closure. This depolarizes GnRH neurons to release GnRH, which stimulates pituitary LH and FSH secretion. The KNDy neuron network (kisspeptin/neurokinin B/dynorphin) in the arcuate nucleus generates the pulsatile GnRH pattern essential for reproductive function.
Key studies supporting the therapeutic use of this peptide.
90-minute IV infusion of kisspeptin-54 at 4 pmol/kg/min increased LH to 10.8 IU/L versus 4.2 with placebo (p < 0.001) and increased FSH to 3.9 versus 3.2 IU/L (p < 0.001). Testosterone was elevated at 180 minutes. Established KP-54 half-life of 27.6 minutes.
Dhillo WS, et al. — J Clin Endocrinol Metab, 90(12):6609-6615 (2005) · PubMed
Oocyte maturation achieved in 95% of patients. Live birth rate at the 9.6 nmol/kg dose was 62%. Zero cases of moderate, severe, or critical OHSS at any dose tested. Biochemical pregnancy rate was 63% and clinical pregnancy rate was 53%.
Abbara A, et al. — J Clin Endocrinol Metab, 100(9):3322-3331 (2015) · PubMed
Two doses of 9.6 nmol/kg kisspeptin-54 separated by 10 hours achieved 71% oocyte yield (60% or greater) versus 45% with single dose (p = 0.042). Live birth rate was 39% dual versus 19.4% single. Zero OHSS cases in the dual-dose group.
Abbara A, et al. — Hum Reprod, 32(9):1915-1924 (2017) · PubMed
IV kisspeptin-10 increased LH from 3.9 to 20.7 IU/L (p = 0.03) and raised testosterone from 8.5 to 11.4 nmol/L (p = 0.002). LH pulse frequency increased from 0.6 to 0.9 pulses per hour.
George JT, et al. — Clin Endocrinol (Oxf), 75(6):746-752 (2013) · PubMed
Typical protocols used in clinical practice. Always consult a licensed provider for personalized dosing.
IV Bolus (Kisspeptin-10)
IV Infusion (Kisspeptin-10)
Subcutaneous Injection (Kisspeptin-54, IVF Trigger)
IV Bolus (Kisspeptin-10): Half-life approximately 4 minutes. Higher doses (3.0 mcg/kg) showed diminished response, suggesting rapid desensitization.
IV Infusion (Kisspeptin-10): Used in the diabetes testosterone recovery study by George et al.
Subcutaneous Injection (Kisspeptin-54, IVF Trigger): Peak LH approximately 45 IU/L at about 5 hours, returning to baseline by 12 to 14 hours.
Kisspeptin-10 has a very short half-life of approximately 4 minutes, while kisspeptin-54 persists for about 28 minutes. Most IVF trigger studies use the longer KP-54 variant for its more sustained effect.
Continuous or twice-daily dosing for more than 2 weeks causes tachyphylaxis through KISS1R internalization and degradation. Intermittent dosing (such as twice-weekly subcutaneous boluses) maintains response for at least 8 weeks without desensitization.
All kisspeptin clinical research has been conducted in controlled medical settings. The peptide is investigational and not approved for any clinical indication outside of research protocols.
No serious adverse events have been reported in any kisspeptin clinical trial to date. Cardiovascular parameters (heart rate and blood pressure), electrolytes, liver function, and renal function remained normal across all studies.
The most significant clinical safety finding is the near-elimination of ovarian hyperstimulation syndrome risk when kisspeptin is used as an IVF trigger. Across all published trials, there were zero cases of moderate, severe, or critical OHSS, representing a 33.6-fold risk reduction compared to hCG trigger.
Kisspeptin acts upstream at the hypothalamic level, and its effect depends on endogenous GnRH and gonadotropin reserves. This provides a built-in safety ceiling because the response is limited by the patient's own physiologic capacity rather than being driven by exogenous supraphysiologic stimulation.
See how Kisspeptin-10 compares to peptides with overlapping benefits.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| Kisspeptin-10 | Reproductive Hormone Regulation | IV or Subcutaneous Injection | Single dose or short-term protocol | Acts at the top of the reproductive hormone cascade (hypothalamic level) to produce physiologic LH surges with near-zero OHSS risk, unlike hCG which acts directly on ovarian LH receptors |
| Tesamorelin | Body Composition & GHRH | Subcutaneous Injection | Ongoing daily | The only FDA-approved GHRH analog with Phase III data in over 800 patients, proven hepatoprotective effects, and physiologic pulsatile GH release |
| Sermorelin | Anti-Aging & GH Restoration | Injection (daily) | 3–6 months | Only GHRH analog with FDA approval history and multi-decade safety record, uniquely preserving natural GH feedback |
| Ibutamoren (MK-677) | Anti-Aging & Body Composition | Oral | 8–16 weeks typical | The only well-studied orally active ghrelin-receptor agonist. Delivers sustained 24-hour IGF-1 elevation without injections, unlike peptide secretagogues such as CJC-1295 or ipamorelin. |
| IGF-1 LR3 | Muscle Growth & Recovery | Injection | 4 to 7 days (animal studies only) | Over 1,000-fold reduction in IGFBP binding removes the natural regulatory brake on IGF-1 signaling, producing extended bioavailability but also eliminating safety controls |
Current FDA classification and compounding eligibility.
The FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.
Listed in Category 2. Kisspeptin-10 is a key regulator of the hypothalamic-pituitary-gonadal axis, studied for ovulation induction, IVF protocols, and hypogonadism diagnosis. FDA cited immunogenicity concerns and limited human safety data for compounding routes. Not eligible for compounding under the interim policy. Not among the 12 peptides HHS withdrew from Category 2 in April 2026.
Listed as 'Kisspeptin-10' in 503A Category 2
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Dhillo WS, et al. “Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males.” J Clin Endocrinol Metab, 90(12):6609-6615 (2005)
Jayasena CN, et al. “Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.” J Clin Endocrinol Metab, 94(11):4315-4323 (2009)
Jayasena CN, et al. “Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54.” J Clin Endocrinol Metab, 99(6):E953-E961 (2014)
Abbara A, et al. “Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy.” J Clin Endocrinol Metab, 100(9):3322-3331 (2015)
Abbara A, et al. “A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.” Hum Reprod, 32(9):1915-1924 (2017)
George JT, et al. “Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.” Clin Endocrinol (Oxf), 75(6):746-752 (2013)
Chan YM, et al. “Kisspeptin resets the hypothalamic GnRH clock in men.” J Clin Endocrinol Metab, 96(6):E908-E915 (2011)
Lippincott MF, et al. “Kisspeptin responsiveness signals emergence of reproductive endocrine activity: implications for human puberty.” J Endocr Soc, 2(11):1261-1274 (2018)
Looking into Kisspeptin-10? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA stabilized 44-residue GHRH analog that stimulates endogenous growth hormone secretion.
FDA-approved as Egrifta for HIV-associated lipodystrophy; strongest clinical evidence of the GHRH analog family.
A 29-residue GHRH analog that prompts the pituitary to release endogenous growth hormone.
Formerly marketed as Geref for pediatric GH deficiency; discontinued in 2008 for commercial reasons.
An orally active ghrelin receptor agonist that elevates growth hormone and IGF-1.
A non-peptide small molecule marketed alongside peptides; named in the April 2026 HHS Category 2 withdrawal for PCAC re-evaluation.